Table I. Preoperative laboratory data and Barcelona-Clinic Liver Cancer Staging was analyzed to determine survival data and disease-free survival data.
| Overall survival | p-Value | Disease-free survival | p-Value | |
|---|---|---|---|---|
| Total cohort | 26 | 14 | ||
| BCLC A1 | a | a | ||
| BCLC A2 | 31 | 31 | ||
| BCLC A3 | 26 | ns | 11 | ns |
| BCLC A4 | 23 | 9 | ||
| BCLC B | 25 | 14 | ||
| BCLC C | b | b | ||
| Size <3 cm | 26 | 12 | ||
| Size 3–5 cm | 26 | ns | 16 | ns |
| Size >5 cm | 25 | 14 | ||
| Number of Lesions <3 | 26 | ns | 17 | ns |
| Number of Lesions ≥3 | 27 | 11 | ||
| Child-Pugh Grade A | 28 | 16 | ||
| Child-Pugh Grade B | 15 | 0.01 | 10 | 0.03 |
| Child-Pugh Grade C | 5 | 3 | ||
| AFP<400 | 29 | 0.002 | 15 | 0.0001 |
| AFP≥400 | 13 | 4 | ||
| No Ascites | 31 | 0.003 | 38 | 0.02 |
| Ascites | 15 | 16 | ||
| Bilirubin <2 (mg/dl) | 27 | 0.01 | 14 | 0.03 |
| Bilirubin ≥2 (mg/dl) | 19 | 5 |
Note: Child-Pugh Grade, AFP, ascites, and bilirubin levels all proved to be statistically significant indicators of survival.
aMedian survival was not reached among this cohort.
bNo patients with BCLC Grade C underwent RFA in this study.